M
Marilyn K. Glassberg
Researcher at University of Arizona
Publications - 125
Citations - 8318
Marilyn K. Glassberg is an academic researcher from University of Arizona. The author has contributed to research in topics: Idiopathic pulmonary fibrosis & Pirfenidone. The author has an hindex of 27, co-authored 110 publications receiving 6498 citations. Previous affiliations of Marilyn K. Glassberg include University of California, San Francisco & University of Miami.
Papers
More filters
Journal ArticleDOI
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis
Talmadge E. King,Williamson Z. Bradford,Socorro Castro-Bernardini,Elizabeth A. Fagan,Ian Glaspole,Marilyn K. Glassberg,Eduard Gorina,Peter Hopkins,David Kardatzke,Lisa Lancaster,David J. Lederer,Steven D. Nathan,Carlos Alberto de Castro Pereira,Steven A. Sahn,Robert Sussman,Jeffrey J. Swigris,Paul W. Noble +16 more
TL;DR: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis.
Journal ArticleDOI
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Paul W. Noble,Carlo Albera,Williamson Z. Bradford,Ulrich Costabel,Marilyn K. Glassberg,David Kardatzke,Talmadge E. King,Lisa Lancaster,Steven A. Sahn,Javier Szwarcberg,Dominique Valeyre,Roland M. du Bois +11 more
TL;DR: In this article, the CAPACITY program was designed to confirm the results of a phase 2 study that suggested that pirfenidone, a novel antifibrotic and anti-inflammatory drug, reduces deterioration in lung function in patients with idiopathic pulmonary fibrosis.
Journal ArticleDOI
Tuberin Regulates p70 S6 Kinase Activation and Ribosomal Protein S6 Phosphorylation A ROLE FOR THE TSC2 TUMOR SUPPRESSOR GENE IN PULMONARY LYMPHANGIOLEIOMYOMATOSIS (LAM)
Elena A. Goncharova,Dmitry A. Goncharov,Andrew J. Eszterhas,Deborah S. Hunter,Marilyn K. Glassberg,Raymond S. Yeung,Cheryl L. Walker,Daniel J. Noonan,David J. Kwiatkowski,Margaret M. Chou,Reynold A. Panettieri,Vera P. Krymskaya +11 more
TL;DR: It is found that ribosomal protein S6 (S6), which exerts translational control of protein synthesis and is required for cell growth, is hyperphosphorylated in the smooth muscle-like cell lesions of LAM patients compared with smooth muscle cells from normal human blood vessels and trachea.
Journal ArticleDOI
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
Paul W. Noble,Carlo Albera,Williamson Z. Bradford,Ulrich Costabel,Roland M. du Bois,Elizabeth A. Fagan,Robert S. Fishman,Ian Glaspole,Marilyn K. Glassberg,Lisa Lancaster,David J. Lederer,Jonathan A. Leff,Steven D. Nathan,Carlos Alberto de Castro Pereira,Jeffrey J. Swigris,Dominique Valeyre,Talmadge E. King +16 more
TL;DR: Analysis of data from three phase 3 trials demonstrated that treatment with pirfenidone for 1 year resulted in clinically meaningful reductions in disease progression in patients with IPF.
Journal ArticleDOI
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
Athol U. Wells,Kevin R. Flaherty,Kevin K. Brown,Yoshikazu Inoue,Anand Devaraj,Luca Richeldi,Teng Moua,Bruno Crestani,Wim A. Wuyts,Susanne Stowasser,Manuel Quaresma,Rainer Georg Goeldner,Rozsa Schlenker-Herceg,Martin Kolb,S. Abe,Myriam Aburto,O. Acosta,C. Andrews,Danielle Antin-Ozerkis,G. Arce,M. Arias,Sergey Avdeev,A. Barczyk,Rebecca Bascom,E. Bazdyrev,Paul Beirne,E. Belloli,M. A. Bergna,E. Bergot,Nitin Y. Bhatt,S. Blaas,Benjamin Bondue,Francesco Bonella,E. Britt,Ketan P. Buch,J. Burk,H. Cai,A. Cantin,D. M. Castillo Villegas,A. Cazaux,S. Cerri,S. Chaaban,Nazia Chaudhuri,Vincent Cottin,B. Crestani,G. Criner,Caroline Dahlqvist,Sonye K. Danoff,J. Dematte D'Amico,Daniel F. Dilling,P. Elias,Neil Ettinger,J. Falk,E. R. Fernández Pérez,A. Gamez-Dubuis,G. Giessel,A. Gifford,Marilyn K. Glassberg,C. Glazer,J. Golden,L. Gómez Carrera,Julien Guiot,R. Hallowell,H. Hayashi,J. Hetzel,Nik Hirani,L. Homik,Ben Hope-Gill,D. Hotchkin,K. Ichikado,M. Ilkovich,Y. Inoue,S. Izumi,E. Jassem,L. Jones,Stéphane Jouneau,Robert J. Kaner,J. Kang,T. Kawamura,Romain Kessler,Y. Kim,K. Kishi,H. Kitamura,M. Kolb,Y. Kondoh,C. Kono,D Koschel,Michael Kreuter,Tejaswini Kulkarni,J. Kus,F. Lebargy,A. León Jiménez,Q. Luo,Yolanda Mageto,Toby M. Maher,S. Makino,Sylvain Marchand-Adam,C. Marquette,R. Martinez,M. Martínez,R. Maturana Rozas,Y. Miyazaki,Sergey Moiseev,Maria Molina-Molina,Lake Morrison,L. Morrow,T. Moua,Anoop M. Nambiar,Yasuhiko Nishioka,Hilario Nunes,M. Okamoto,Justin M. Oldham,Maria Otaola,Maria Padilla,J. S. Park,Nina Patel,Alberto Pesci,W. Piotrowski,L. Pitts,H. Poonyagariyagorn,Antje Prasse,Silvia Quadrelli,W. Randerath,R. Refini,M. Reynaud-Gaubert,F. Riviere,J. A. Rodríguez Portal,Ivan O. Rosas,M. Rossman,Zeenat Safdar,T. Saito,N. Sakamoto,M. Salinas Fénero,J. Sauleda,Shelley L. Schmidt,Mary Beth Scholand,M. Schwartz,Shane Shapera,Oksana A. Shlobin,B. Sigal,A. Silva Orellana,Dirk Skowasch,J. W. Song,S. Stieglitz,Helen Stone,Mary E. Strek,T. Suda,H. Sugiura,H. Takahashi,H. Takaya,T. Takeuchi,Krishna Thavarajah,Leslie Tolle,S. Tomassetti,K. Tomii,Claudia Valenzuela,Carlo Vancheri,F. Varone,Srihari Veeraraghavan,A. Villar,S. Weigt,L. Wemeau,W. Wuyts,Z. Xu,V. Yakusevich,Y. Yamada,H. Yamauchi,D. Ziora +167 more
TL;DR: The INBUILD trial suggests that nintedanib reduces the rate of ILD progression, as measured by FVC decline, in patients who have a chronic fibrosing ILD and progressive phenotype, irrespective of the underlying ILD diagnosis.